Clinical Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background: Older adults are at increased risk of severe influenza outcomes, partly due to reduced immune responses to standard-dose vaccines. High-dose influenza vaccines were thus developed to enhance protection, but evidence of their clinical outcomes and safety remains evolving. Methods: A systematic review and meta-analysis of randomized controlled trials examining the efficacy of high-dose versus standard-dose inactivated influenza vaccines in adults aged ≥65 years was performed. PubMed, Embase, Cochrane Library, and Web of Science were searched from inception to January 1, 2026. Clinical outcomes included influenza occurrence, influenza- or pneumonia-related hospitalization, all-cause hospitalization, mortality, and serious adverse events. Random-effects models were used to pool effect estimates. Results: Eight randomized controlled trials including 610,266 participants were analyzed. High-dose influenza vaccination significantly reduced hospitalization due to influenza compared with standard-dose vaccination (odds ratio [OR] 0.71, 95% confidence interval [CI] 0.61–0.81; I² = 0%) and modestly reduced hospitalization due to respiratory infection (OR 0.88, 95% CI 0.82–0.95; I² = 53.8%). No statistically significant differences were observed for all-cause hospitalization (OR 0.90, 95% CI 0.80–1.01; I² = 80.5%) or all-cause mortality (OR 0.96, 95% CI 0.90–1.03; I² = 58.6%). Serious adverse events were comparable between groups (OR 1.00, 95% CI 0.97–1.02; I² = 0%). Absolute reductions corresponded to 135 fewer influenza hospitalizations and 266 fewer respiratory infection hospitalizations among high-dose vaccine recipients. Conclusions: High-dose inactivated influenza vaccines improve protection against influenza and influenza-related hospitalization in older adults without increasing serious adverse events. However, their implementation should be considered in the context of local epidemiology, healthcare resources, and policy priorities.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Question
Published
2026-03-22
DOI
https://doi.org/10.69854/jcq.2026.0008
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ryo Orii, Kentaro Yumoto, Mai Kaneko, Shohei Watanabe et al.
Journal of Clinical Question
Influenza Virus Research Studies
article

Clinical Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ryo Orii, Kentaro Yumoto, Mai Kaneko, Shohei Watanabe, Reeko Osada
article en

Abstract

Background: Older adults are at increased risk of severe influenza outcomes, partly due to reduced immune responses to standard-dose vaccines. High-dose influenza vaccines were thus developed to enhance protection, but evidence of their clinical outcomes and safety remains evolving. Methods: A systematic review and meta-analysis of randomized controlled trials examining the efficacy of high-dose versus standard-dose inactivated influenza vaccines in adults aged ≥65 years was performed. PubMed, Embase, Cochrane Library, and Web of Science were searched from inception to January 1, 2026. Clinical outcomes included influenza occurrence, influenza- or pneumonia-related hospitalization, all-cause hospitalization, mortality, and serious adverse events. Random-effects models were used to pool effect estimates. Results: Eight randomized controlled trials including 610,266 participants were analyzed. High-dose influenza vaccination significantly reduced hospitalization due to influenza compared with standard-dose vaccination (odds ratio [OR] 0.71, 95% confidence interval [CI] 0.61–0.81; I² = 0%) and modestly reduced hospitalization due to respiratory infection (OR 0.88, 95% CI 0.82–0.95; I² = 53.8%). No statistically significant differences were observed for all-cause hospitalization (OR 0.90, 95% CI 0.80–1.01; I² = 80.5%) or all-cause mortality (OR 0.96, 95% CI 0.90–1.03; I² = 58.6%). Serious adverse events were comparable between groups (OR 1.00, 95% CI 0.97–1.02; I² = 0%). Absolute reductions corresponded to 135 fewer influenza hospitalizations and 266 fewer respiratory infection hospitalizations among high-dose vaccine recipients. Conclusions: High-dose inactivated influenza vaccines improve protection against influenza and influenza-related hospitalization in older adults without increasing serious adverse events. However, their implementation should be considered in the context of local epidemiology, healthcare resources, and policy priorities.

Journal of Clinical QuestionVol. 3(2)
Yokohama Minami Kyosai Hospital (JP)
Good health and well-being
Openalex Percentile: Top 16%
Influenza Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.